Biomarin Pharmaceutical Inc (BMRN)

Add to Watchlists
Create an Alert
Quickflows
76.73 -1.78  -2.27% NASDAQ Jul 30, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All BMRN News

News

View All Events

Events

Date Type Description
11/05/2021 Earnings Results Q3 2021 Earnings Results
11/05/2021 16:30 EST Earnings Calls Q3 2021 Earnings Call
07/28/2021 Earnings Results Q2 2021 Earnings Results
07/28/2021 16:30 EST Earnings Calls Q2 2021 Earnings Call
05/25/2021 12:00 EST AGM 2020 Annual General Meeting
04/29/2021 Earnings Results Q1 2021 Earnings Results
04/29/2021 16:30 EST Earnings Calls Q1 2021 Earnings Call
02/25/2021 Earnings Results Q4 2020 Earnings Results
02/25/2021 16:30 EST Earnings Calls Q4 2020 Earnings Call
11/05/2020 Earnings Results Q3 2020 Earnings Results
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 1.917B
Total Expenses (TTM) 1.974B
Net Income (TTM) 837.21M

Balance Sheet View Statement

Total Assets (Quarterly) 5.898B
Total Liabilities (Quarterly) 1.657B
Shareholders Equity (Quarterly) 4.242B

Cash Flow Statement View Statement

Cash from Operations (TTM) 269.12M
Cash from Investing (TTM) -73.32M
Cash from Financing (TTM) -376.31M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
  • URL: http://www.bmrn.com
  • Investor Relations URL: https://investors.biomarin.com
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Blend
  • Next Earnings Release: Nov. 05, 2021
  • Last Earnings Release: Jul. 28, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 76.73
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
GNOM Global X Genomics & Biotechnology ETF 4.04%
FBT First Trust NYSE Arca Biotech ETF 3.26%
BBH VanEck Vectors Biotech ETF 2.42%
FCTR First Trust Lunt US Factor Rotation ETF 2.13%
VHCOX Vanguard Capital Opportunity Inv 2.07%
ATL6737 Renaissance Global Science & Tech Cl O (USD) 2.05%
BTEC Principal Healthcare Innovators ETF 2.03%
RYCFX Rydex Biotechnology C 1.54%
POGRX PRIMECAP Odyssey Growth 1.38%
POAGX PRIMECAP Odyssey Aggressive Growth 1.32%
IBB iShares Biotechnology ETF 1.06%
CAFFX American Funds AMCAP 529F1 0.98%

Comparables

Edit
PFE Pfizer Inc
VRTX Vertex Pharmaceuticals Inc
RGEN Repligen Corp
BMY Bristol-Myers Squibb Co
ACAD ACADIA Pharmaceuticals Inc

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.